Compare BSTZ & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSTZ | ATAI |
|---|---|---|
| Founded | 2019 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | N/A | 2021 |
| Metric | BSTZ | ATAI |
|---|---|---|
| Price | $21.48 | $3.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $15.57 |
| AVG Volume (30 Days) | 208.6K | ★ 4.6M |
| Earning Date | 01-01-0001 | 03-06-2026 |
| Dividend Yield | ★ 8.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | N/A | ★ $308,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $30.92 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.22 | $1.15 |
| 52 Week High | $23.47 | $6.73 |
| Indicator | BSTZ | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 43.03 | 39.71 |
| Support Level | $20.60 | $3.06 |
| Resistance Level | $23.21 | $4.30 |
| Average True Range (ATR) | 0.45 | 0.21 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 21.53 | 6.09 |
BlackRock Science and Technology Trust II is a non-diversified, closed-end management investment company. The trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation. Its portfolio consists of Equity Securities, Options, Preferred Securities, Convertible Securities, Depositary Receipts, Non-U.S. Securities, Emerging Markets Investments, Restricted and Illiquid Investments, Private Company Investments, Corporate Bonds, and other investments. The trust seeks to Invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range from the development, advancement, and use of science and/or technology.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.